Kidney cancers have been extensively studied, and insights from an increased
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …

Renal cell carcinomas vary considerably in their tumor biology and disease course, which is
reflected in the range of treatment paradigms in localized and metastatic renal cell …

Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-
cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies …

Importance In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC)
have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the …

Background The features and survival of stage IV breast cancer patients with different
metastatic sites are poorly understood. This study aims to examine the clinicopathological …

Sarcomatoid dedifferentiation is an uncommon feature that can occur in most histological
subtypes of renal cell carcinomas (RCCs) and carries a decidedly poor prognosis …

Purpose Following curative treatment for localised renal cell carcinoma (RCC), up to 30% of
patients develop tumour recurrence. Prognostic scores are essential to guide individualised …

Abstract Context The European Association of Urology Guideline Panel for Renal Cell
Carcinoma (RCC) has prepared evidence-based guidelines and recommendations for RCC …

Over the past decade, the treatment landscape for patients with metastatic renal cell
carcinoma (RCC) has evolved dramatically. The therapeutic options available have …

Context The role of cytoreductive nephrectomy (CN) in the management of metastatic renal
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …